Angiotensin II Type-1 Receptor Blockers Enhance the Effects of Bevacizumab-Based Chemotherapy in Metastatic Colorectal Cancer Patients

Molecular and Clinical Oncology - United Kingdom
doi 10.3892/mco.2015.630
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Spandidos Publications

Related search

Organoprotecive Effects of Angiotensin II Receptor Blockers in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus
Internal MedicineEndocrinologyMetabolismDiabetes
2010English

Hypertension and Overall Survival in Metastatic Colorectal Cancer Patients Treated With Bevacizumab-Containing Chemotherapy

British Journal of Cancer
Cancer ResearchOncology
2011English

Adverse Events Associated With Bevacizumab and Chemotherapy in Older Patients With Metastatic Colorectal Cancer

Clinical Colorectal Cancer
OncologyGastroenterology
2013English

Polymorphisms of the Angiotensin II Type 1 Receptor Gene Affect Antihypertensive Response to Angiotensin Receptor Blockers in Hypertensive Chinese

Genetics and Molecular Research
MedicineGeneticsMolecular Biology
2013English

Effect and Safety of Bevacizumab-Containing Chemotherapy Treatment in Chinese Patients With Metastatic Colorectal Cancer

OncoTargets and Therapy
OncologyPharmacology
2013English

Perioperative Chemotherapy With or Without Bevacizumab in Patients With Metastatic Colorectal Cancer Undergoing Liver Resection

Clinical Colorectal Cancer
OncologyGastroenterology
2013English

Angiotensin II Type 1 Receptor Blockers Inhibit KAT II Activity in the Brain—Its Possible Clinical Applications

Neurotoxicity Research
NeuroscienceToxicology
2017English

Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer

JAMA Oncology
Cancer ResearchOncology
2019English

Bevacizumab May Overcome Clinical Tumor Drug Resistance to Irinotecan Based Chemotherapy in Patients With Metastatic Colorectal Cancer: Case Report

The Open Colorectal Cancer Journal
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy